Protective effect of Daming capsule against chronic cerebral ischemia by unknown
Song et al. BMC Complementary and Alternative Medicine  (2015) 15:149 
DOI 10.1186/s12906-015-0668-6RESEARCH ARTICLE Open AccessProtective effect of Daming capsule against
chronic cerebral ischemia
Xiaodan Song1,2, Wenliang Zhu1, Ran An1, Yamei Li1 and Zhimin Du1,3*Abstract
Background: Accumulating evidence has shown that chronic cerebral ischemia (CCI) is one of the major causes of
vascular dementia (VD) characterized by dysregulated cholesterol homeostasis and lipoprotein disturbances. Positive
value of lipid-lowering agents has been widely evaluated for the treatment of VD. In the present study, we investigated
whether Daming capsule (DMC) protected against CCI-induced VD and its possible mechanisms of action. DMC is a
multi-herbal formula composed of Rheum palmatum L., Cassia obtusifolia L., Salvia miltiorrhiza, and Panax ginseng C.A.,
which has been used to treat hyperlipidemia for years in China.
Methods: A network pharmacology method was established to reveal whether DMC contained any chemical
constituent targeting CCI-related proteins. Furthermore, the potential anti-CCI effects of DMC (100 mg/kg or
200 mg/kg) administered for 30 days were investigated in vivo on rats that were subjected to permanent
bilateral occlusion of the carotid arteries (2-VO). Spatial learning and memory abilities were evaluated using a
Morris water maze (MWM) and morphological changes of cerebral cortex and hippocampus were assessed using
hematoxylin and eosin staining. Moreover, the lipid peroxidation levels and antioxidative capabilities were
measured using biochemical analysis.
Results: Our network pharmacology analysis revealed the existence of multiple CCI-related chemical-target
interactions in DMC, suggesting a potential protective effect. An in vivo experiment verified that 200 mg/kg
DMC improved cognitive deficits of 2-VO rats in the MWM test and attenuated pathological alterations in both
the cerebral cortex and the hippocampus. Biochemical assays indicated that DMC decreased malondialdehyde
levels and CCI-elevated superoxide dismutase activities, but increased the activities of glutathione peroxidase
and catalase.
Conclusions: Our findings suggested that DMC protected against cognitive dysfunction and nerve injuries
caused by CCI, which is most likely related to its antioxidant actions.
Keywords: Daming capsule, Chronic cerebral ischemia, Morris water maze test, AntioxidantBackground
Vascular dementia (VD) is the second most common
cause of dementia, after Alzheimer’s disease, in the eld-
erly population [1]; it includes cognitive function decline
and brain structure damages [2]. It has been revealed
that hypertension, diabetes, and hypercholesterolemia
are crucial risk factors for the pathogenesis and* Correspondence: dzm1956@126.com
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© 2015 Song et al.development of VD [3–5]. Increasingly, evidence sug-
gests that the pathogenesis of VD is closely related to
cholesterol homeostasis and lipoprotein disturbance [6, 7].
This led to extensive assessment of lipid-lowering agents
by many researchers in the field of VD.
Considerable evidence indicates that chronic cere-
bral ischemia (CCI) is a major cause of VD [8, 9].
Ischemic cerebrovascular diseases, such as CCI, are
characterized by vessel lesions. Similar mechanisms of
ischemic cardiovascular disease were found in CCI
[10]. Among them, oxidative stress and disturbed cel-
lular pro-oxidant—antioxidant status play vital roles in
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oxidative stress is an important therapeutic strategy for
CCI treatment.
Daming capsule (DMC), a multi-herbal formula, has
been used clinically to treat hyperlipidemia for years in
China; it is composed of four herbs, including Rheum
palmatum L., Cassia obtusifolia L., Salvia miltiorrhiza,
and Panax ginseng C.A. DMC was reported to have mul-
tiple pharmacological activities, such as preventing cardiac
dysfunction [12], resisting free radicals [13, 14], improving
lipidemia conditions [15, 16], decreasing blood glucose
levels [17], protecting against myocardial ischemia reper-
fusion injury, reducing myocardial infarctions [18, 14],
and restoring aortic endothelial dysfunction [17, 19].
Rheum palmatum L., the monarch component of DMC,
was validated to promote blood circulation, dissipate
blood stasis, and protect rats with cerebral ischemia
[20]. Cassia obtusifolia L. attenuates memory impair-
ment induced by scopolamine or permanent bilateral
occlusion of the carotid arteries (2-VO) [21]. Moreover,
Salvia miltiorrhiza [22] and Panax ginseng C.A. [23]
have shown beneficial effects on many nervous system
diseases. Taken together, the above studies strongly
suggest therapeutic potential of DMC in CCI.
Recently, network pharmacology has been utilized to
virtually evaluate the pharmacological effects of traditional
Chinese medicine (TCM) as a whole. By mapping the
polypharmacology network, researchers predict the clin-
ical curative effects of TCM and explore the potential
drug targets related to the specific disease [24]. Recently, a
network pharmacology-based strategy, called “network
target, multi-components,” was put forward, which was
thought to provide a more comprehensive and realistic
understanding of TCM [25]. In this study, a network
pharmacology method was established to predict the po-
tential therapeutic effects of DMC on CCI by mapping
CCI-related polypharmacology networks. Next, a 2-VO
rat model of CCI was used in vivo to assess the effects of
DMC on cognitive deficits, histopathological changes, and
oxidative stress after 2-VO injury. Such efforts aim to
determine whether DMC has potential therapeutic value
for the treatment of CCI.
Methods
Chemicals and reagents
DMC (Drug Approval Number: Z20030085) was pro-
vided by Harbin Yida Co., Ltd. (Harbin, China).
Hydergine (Batch No. 2K847T) was purchased from
Tianjin Huajin Pharmaceutical Co., Ltd. (Tianjin, China).
Malondialdehyde (MDA), superoxide dismutase (SOD),
glutathione peroxidase (GPx), and catalase (CAT) kits
were purchased from Nanjing Jiancheng Bioengineering
Institute (Nanjing, China). Other reagents were of analyt-
ical grade.Collection of information about DMC compounds and
related targets
The information about DMC compounds was obtained
from the TCM Database @Taiwan [26]. After that, the
STITCH 3.1 database was used to search for correspond-
ing targets to these constituents [27]. We only retained
targets with high confidence scores (>0.7) in Homo sapi-
ens. The compounds with many targets (n >50) were dis-
carded to avoid overestimation of the potential effects of
DMC on CCI. Next, the HuGE Navigator was applied to
obtain experimentally validated CCI-related genes [28].
Construction of CCI-specific target-constituent-herb
association networks for DMC
We integrated constituent-herb associations and constitu-
ent-target associations and imported it into Cytoscape
v2.8.3 [29] to establish four target-constituent-herb associ-
ation networks, in which targets, chemicals, and herbs
were represented as nodes with different shapes. The
gene-CCI associations were also imported as node attri-
butes. If a target was not associated with CCI, it was de-
leted from the network.
Animals and establishment of a 2-VO rat model
Adult male Sprague-Dawley rats (250–300 g) were pur-
chased from the Animal Center of the 2nd Affiliated
Hospital of Harbin Medical University (Harbin, China).
All animals were housed in a room with a controlled
temperature of 23 ± 1 °C and humidity of 55 ± 5 % with
a regular 12 h light-dark cycle and provided free access
to water and food. All experimental procedures regard-
ing the animals were approved by the ethic committees
of Harbin Medical University. The rats were acclima-
tized to the housing conditions for at least 4 days before
use. All behavioral tests were performed between
8:00 a.m. and 17:30 p.m. CCI was induced by 2-VO ac-
cording to the procedures described before [30]. Rats
were anesthetized with 10 % chloral hydrate [350 mg/kg,
intraperitoneal injection (i.p.)]. Briefly, the bilateral com-
mon carotid arteries of rats were separated through a
midline cervical incision, from the cervical sympathetic
and vagal nerves, and double ligated with 5–0 silk
suture. The sham group received the same operation
without the arterial ligation. During the surgery, the rat’s
body temperature was maintained at 37.5 ± 0.5 °C using
a heating pad until they recovered from anesthesia.
Then, all the animals were housed in cages with food
and water ad libitum and used after one week of quar-
antine and acclimatization.
Drug administration
On the eighth day after surgery, the 2-VO rats were ran-
domly assigned to four groups: (1) the rats in the 2-VO
group were administered saline, the rats in the DMCl
Table 1 Validated CCI-related target-constituent interactions in
DMC
Herb Constituent (n) Gene (n) Target constituent
interaction
Rheum palmatum L. 7 9 14
Cassia obtusifolia L. 4 4 4
Salvia miltiorrhiza 11 16 30
Panax ginseng C.A. 6 6 8
Total 25 27 55
CCI: Chronic cerebral ischemia; DMC: Daming capsule
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(3) the rats in the DMCh group were administered high-
dose (200 mg/kg) DMC, and (4) the rats in the HYD
group were administered 0.6 mg/kg Hydergine. Rats in
the sham group were administered saline. Rats were
orally administered the drug once daily at 8:00 am.
Hydergine was dissolved in saline and used as a positive
control. The common human daily dose of DMC is
1.8 g/60 kg/d of body weight. According to the formula:
d/rat = d/human × 0.71/0.11 [31], the corresponding
dose of DMC for rats was 187 mg/kg/d. Therefore,
200 mg/kg/d and 100 mg/kg/d were chosen as the high
and low doses, respectively. DMC powder was sus-
pended in saline; the dosage volume was 10 mL/kg.
Morris water maze (MWM) test
In order to investigate the effect of DMC on 2-VO-
induced learning and memory impairment, the spatial
learning and memory performance of rats were tested
using the MWM test [32]. The MWM test was con-
ducted after drug administration for 30 days. Escape
latency was used to assess learning and the memory of
the rats. If the rat failed to locate the platform within
90 s, the training was terminated and a maximum score
of 90 s was assigned. The rat was then guided to the
hidden platform and allowed to stay on the platform
for 30 s before being removed from the water. A com-
puter tracking program was started as soon as the rats
were released into the water and stopped when the
rats climbed on the platform or did not locate the
platform within 90 s. After the last training trial on
day 5, the platform was removed from the pool and
the rats were allowed to swim for 90 s by the probe
trials; the swimming distance in the target quadrant
without the platform was used to evaluate leaning
ability.
Histopathological examination
Rats were deeply anesthetized with chloral hydrate
(350 mg/kg, i.p.) after the behavioral test and were per-
fused through the left cardiac ventricle with 100 mL
saline, followed by 4 % paraformaldehyde in phosphate
buffer. Then, the brain of each rat was removed and
fixed by immersion in the same fixative at 4 °C. The
fixed brains were dehydrated and embedded in paraffin
blocks. They were cut into 4-mm thick serial sections.
These sections were then stained with hematoxylin and
eosin and examined for brain damage under a light
microscope (magnification × 200) by an examiner blinded
to experimental conditions.
Biochemical analysis
Rats were decapitated under anesthesia after the MWM
test. The brains were rapidly removed, and then thehippocampus and cerebral cortex were removed separately
and placed in ice-cold saline, blotted dry, weighed, and
then immediately frozen and stored at −80 °C until
biochemical assays were performed. Then, tissue sam-
ples were cut into pieces and homogenized in ice-cold
saline to yield 10 % (w/v) homogenates. The oxidant
and antioxidant status of the cerebral cortex and
hippocampus of rats subjected to CCI was assessed by
measuring the MDA levels and the activities of SOD,
GPx, and CAT, according to the manufacturer’s in-
structions. Protein content was determined using the
Bradford method [33].
Statistical analysis
All results were presented as mean ± SEM. GraphPad
Prism v6.0 software was used for statistical evaluation.
One-way analysis of variance followed by the Tukey’s
test was used to analyze data. The level of significance
was established at p <0.05.
Results
Multiple constituents in DMC were associated with CCI
In total, 298 constituents were found in DMC and 55
target-constituent associations related to CCI were
identified (Table 1). After integrating experimental evi-
dence from multiple sources, four CCI-specific target-
constituent-herb association networks were constructed
for DMC, as shown in Fig. 1, in which multiple constitu-
ents were found to be associated with CCI-related tar-
gets in one herb. Multiple constituents in one herb had
common CCI-related targets.
DMC attenuated learning and memory impairment
induced by 2-VO
In the MWM test, rats of all groups were efficient at
locating the platform after successive trials. As shown in
Fig. 2 (a–e), the escape latencies of rats decreased grad-
ually in all groups during the five day test. For the first
two days of the training trials, the escape latencies did
not differ significantly between groups. However, the
2-VO group exhibited a longer latency to locate the
platform than the sham group (p <0.05, Fig. 2c) from
Fig. 1 CCI-specific target-chemical-herb association networks for RP (a), CO (b), SM (c), and PG (d) in DMC. Diamond, hexagonal, and rectangular
nodes represent targets, chemicals, and herbs, respectively. Edges represent validated associations between chemicals and the target or herbs.
CCI: chronic cerebral ischemia; DMC: Daming capsule; RP: Rheum palmatum L.; CO: Cassia obtusifolia L.; SM: Salvia miltiorrhiza; PG: Panax
ginseng C.A
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CCI caused obvious learning and memory impairment
in 2-VO rats. The escape latency of the DMCl group
was shorter than that of 2-VO group, but not significantly
different. The escape latency of the DMCh group signifi-
cantly decreased on the fifth day (p < 0.05), similar to that
observed for the 0.6 mg/kg HYD group (Fig. 2e). In the
probe trials, the percentage of swimming distance in the
target quadrant of the 2-VO group significantly decreased
compared to the sham group. Compared to the 2-VO
group, the percentage of swimming distance in the target
quadrant of the DMCh and HYD groups significantly in-
creased (p <0.05, Fig. 2f). Furthermore, the swimming
paths of the 2-VO and DMCl groups were uniformly dis-
tributed around the four quadrants, while the swimmingpaths of the other groups focused on the target quadrant
(Fig. 3).
DMC reversed CCI-induced morphological changes of the
cerebral cortex and hippocampus
Hematoxylin and eosin staining was used to survey the
morphological changes in the cerebral cortex and hippo-
campus after CCI and the effects of drug treatment. As
shown in Fig. 4, prominent morphological changes, such
as neuronal cell loss, nuclei shrinkage, glial proliferation,
and dark staining of neurons, were visualized in the
cerebral cortex and hippocampus of the 2-VO group.
DMC (200 mg/kg) prevented CCI-induced histological
injuries in the rat brain, similar to that found in the
HYD group.
Fig. 2 Effect of DMC on CCI-induced cognitive deficits as measured by MWM test (n = 8). a–e Escape latency from day 1 to day 5. f The percentage of
distance in the 4th quadrant. * p <0.05, ** p <0.01, *** p <0.001 compared to the Sham; # p <0.05, ## p <0.01 compared to the 2-VO group. CCI: chronic
cerebral ischemia; DMC: Daming capsule
Fig. 3 Measurement of the swimming paths
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and CAT in the cerebral cortex and hippocampus
The MDA levels in the cerebral cortex and hippocampus
and the SOD activity in cerebral cortex significantly in-
creased in the 2-VO group compared to the sham group
(p <0.05, Fig. 5a–d). After repeated administration of
200 mg/kg DMC, the content of MDA in the two brain
regions and the SOD activity in the cerebral cortex sig-
nificantly decreased compared to the corresponding
values in the 2-VO group (p <0.05), whereas administra-
tion of 100 mg/kg DMC had modest effects. The SOD
activity in the hippocampus did not differ across the
groups and a slight increase in the SOD activity was ob-
served only in the 2-VO group. Both the GPx and CAT
activities significantly decreased in the cerebral cortex
and hippocampus in the 2-VO compared to the sham
group (p <0.05, Fig. 5e–h). The activities of GPx and
CAT in the DMCh group were significantly higher than
that observed in the 2-VO group in the two brain re-
gions (p <0.05, Fig. 5e–h).
Discussion
In the present study, we demonstrated for the first time
that DMC improved cognitive deficits and alleviated neur-
onal injury induced by CCI in rats. This therapeutic benefit
was partly related to the anti-oxidative properties of DMC.
A network pharmacology method was employed for in
silico predicting potential pharmacological action of DMC
on CCI by constructing CCI-specific target-constituent-herb
Fig. 4 Representative photomicrographs of the rat hippocampus (a) and cerebral cortex (b) after CCI. Magnification × 200. CCI: chronic cerebral
ischemia; DMC: Daming capsule
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pharmacology was widely applied as an effective tool to
uncover new potential clinical applications for TCM. Our
results revealed potential therapeutic effects of DMC on
CCI. Multiple CCI-related chemical-target interactions
were found in each of the networks. This finding was
in-line with the results of previous functional studies
that reported that DMC showed multiple effects against
ischemia because it contained many chemicals influencing
the phenotype of ischemia. Studies on DMC validated its
antioxidant properties against lipid peroxidation and free
radical scavenging in myocardial ischemia rats [13, 14].
Oxidative stress was associated with apoptosis [34] and
the activities of matrix metalloproteinases (MMPs) [35].
Four proteins, p53, MMP1, MMP3, and MMP9, are
involved in the networks. Moreover, DMC could abate
myocardial cell inflammation [18] and reduce vascular
endothelial injury [19]. Consistently, the related proteins,
such as IL6, IL1B, TNF, ACE, EDN1, VEGFA, and ICAM1,
could be seen in our networks. It has been reported that
DMC has lipid-lowering actions [16]. This evidence could
be reflected the existence of ADIPOQ in the network.
Additionally, two proteins, NOS3 and IGF1, were present
in the network. This is in-line with the protective effects
of DMC against endothelial dysfunction of the aorta in
high fat diet rats via upregulation of NOS3 expression [19]
and the beneficial effects on diabetic symptoms [17].
Taken together, we hypothesized that DMC is a protective
agent against CCI. The following in vivo experiments vali-
dated our hypothesis.
CCI could lead to severe memory and learning deficit,
which closely resembles the reduced cerebral blood flow
that occurs with dementia [8]. The 2-VO surgery was
used to build an experimental model mimicking the
pathophysiology of learning and memory deficits associ-
ated with CCI. The MWM test is the recognized methodfor evaluating spatial learning and memory [32]. Com-
pared to the sham rats, the 2-VO rats showed an inferior
performance in the training and probe trials, indicating
impaired spatial learning and memory after CCI. Admin-
istration of a high dose of DMC to 2-VO rats improved
the scores on the behavioral test, indicating benefits of
DMC treatment.
CCI caused lesions on the cerebral cortex and hippo-
campus, which have a direct correlation to severe mem-
ory loss and learning deficit [36]. Consistent with the
previous studies, our histological staining results con-
firmed that CCI induced severe pathological changes in
the brain. Neurons in the cerebral cortex and hippocam-
pus were degenerated after CCI. Administration of a
high dose of DMC attenuated the 2-VO induced neur-
onal damage. This observation was consistent with the
behavioral test results.
Oxidative stress is closely associated to neuronal degen-
eration, which is involved in the pathogenesis of numer-
ous neurodegenerative diseases [37]. Permanent cerebral
hypoperfusion produced abnormal changes in free radicals
in the brain [38]. Excessive generation of reactive oxygen
species (ROS) results in neuronal cellular damage due to
the oxidation of membrane lipids, essential cellular pro-
teins, and DNA [39]. MDA is a product of lipid peroxida-
tion that is used to assess the degree of cell destruction by
free radicals. We discovered that the MDA content signifi-
cantly increased in both the cerebral cortex and hippo-
campus of the 2-VO group. The SOD activity increased in
the 2-VO group. This was a compensatory rise in antioxi-
dant activity in response to increased free radical gener-
ation [40]. Our results were consistent with previous
reports [41]. Activation of SOD did not provide neuronal
protection because SOD catalyzes the conversion of
superoxide anions to hydrogen peroxide, which is usually
considered more cytotoxic than the oxygen-derived free
Fig. 5 Effect of DMC on the status of oxidative stress and the activities of SOD, GPx, and CAT in the cerebral cortex and hippocampus of rats
with CCI (n = 5). DMC decreased the MDA levels in the cerebral cortex (a) and hippocampus (b). * p <0.05, ** p <0.01 compared to the Sham
group; # p <0.05, ## p <0.01 compared to the 2-VO group. c DMC reduced the SOD activity in the cerebral cortex of rats with CCI. * p <0.05
compared to the Sham group; # p <0.05 compared to the 2-VO group. d No significant change in the SOD levels was found in the hippocampus
of rats with CCI. DMC enhanced GPx activity in the cerebral cortex (e) and hippocampus (f) of rats with CCI. * p <0.05 compared to the Sham
group; # p <0.05, compared to the 2-VO group. DMC elevated CAT activity in the cerebral cortex (g) and hippocampus (h). * p <0.05, ** p <0.01
compared to the Sham group; # p <0.05, compared to the 2-VO group. CCI: chronic cerebral ischemia; DMC: Daming capsule
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gen peroxide [42]. The elimination of hydrogen peroxide
is critical in reducing oxidative stress that is induced by
CCI. GPx and CAT activity significantly decreased in the
cerebral cortex and hippocampus in the 2-VO group. The
increase in the MDA levels and the SOD activity is indica-
tive of an increase in the oxidative stress process, whereas
a decrease in the GPx and CAT activities indicated insuffi-
cient endogenous antioxidant ability. Compared to the 2-
VO group, administration of a high dose of DMC dimin-
ished MDA production, reversed abnormal SOD activity
in the cerebral cortex, and enhanced the GPx and CATac-
tivities. These results suggested that DMC may reverse
the abnormality of free radicals and compensate antioxi-
dant abilities following CCI insult. This finding is consist-
ent with previous results that suggest that DMC showed
antioxidant properties against lipid peroxidation and free
radical scavenging in myocardial ischemia rats [13, 14].
Just recently, a UPLC-ESI-Q-TOF-MS/MS method
was applied by us to identify 31 compounds in DMC,
among which 6 anthraquinones including chrysophanol,
emodin, aloe-emodin, rhein, emodin-O-glucoside and
aurantio-obtusin were revealed as potential lipid-lowering
bioactive components in DMC [43]. By enhancing brain
tissue hypoxia tolerance, chrysophanol was validated to
protect neuron damage and improve learning and mem-
ory abilities [44, 45]. Emodin exhibited ameliorating ef-
fects on cycloheximide-induced memory consolidation
impairment in rats [46] and antioxidative stress damage of
rat cortical neurons induced by Aβ25–35 [47]. Aloe-emodin
showed protective effects on the scopolamine-induced
memory impairment in mice and hydrogen peroxide-
induced cytotoxicity in PC12 cells [48]. Rhein protected
against oxidative stress-related endothelial cell injury [49].
Emodin-O-glucoside improved the learning and memory
of both normal and intelectual deficit mice induced by
scopolamine [50]. There is no evidence indicating that
aurantio-obtusin has protective effect against CCI. How-
ever, it has been proved of lipid-regulating effect [51].
Taken together, we suppose that the first 5 compounds in-
cluding chrysophanol, emodin, aloe-emodin, rhein and
emodin-O-glucoside be the material basis of the anti-CCI
effect of DMC that was shown herein.
Conclusions
In summary, the present study predicted the potential
pharmacological actions of DMC on CCI using the
network pharmacology method and experimentally dem-
onstrated that DMC inhibited cognitive decline and
neuronal damage induced by CCI in rats. The protective
effects of DMC on CCI were closely associated with
multiple bioactive components and its antioxidant ac-
tion. The results suggested that DMC might be effective
for managing VD.Abbreviations
VD: Vascular dementia; DMC: Daming capsule; CCI: Chronic cerebral ischemia;
MWM: Morris water maze; MDA: Malonic dialdehyde; 2-VO: Permanent
bilateral occlusion of carotid arteries; SOD: Superoxide dismutase;
TCM: Traditional Chinese medicine; GPx: Glutathione peroxidase;
CAT: Catalase.
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